Table 1.
Total, n = 149 | 30-d Survivors, n = 93 | 30-d Non-survivors n = 56 | p-value | |
---|---|---|---|---|
Demographics | ||||
Female | 78 (52.3) | 50 (53.7) | 28 (50) | 0.65 |
Age, median (IQR) | 47 (32–58) | 44 (30–55) | 48 (35.5–61.5) | 0.23 |
Intensive care unit admission | 37 (24.8) | 15 (16.1) | 22 (39.2) | < 0.001 |
APACHE II n = 122, median (IQR) | 18 (14–24) | 16 (12–20) | 23 (18.5–28.5) | < 0.001 |
Severe sepsis | 66 (44.3) | 29 (31.1) | 37 (66) | < 0.001 |
Comorbidities | ||||
Hematologic neoplasia | 45 (30.2) | 22 (23.6) | 23 (41) | 0.025 |
Solid neoplasia | 26 (17.4) | 17 (18.2) | 9 (16) | 0.73 |
Cardiovascular | 37 (24.8) | 22 (23.6) | 15 (26.7) | 0.7 |
Chronic kidney disease | 18 (12) | 10 (10.7) | 8 (14.2) | 0.52 |
Cirrhosis | 11 (7.3) | 1 (1) | 10 (17.8) | < 0.001 |
Diabetes mellitus | 19 (12.7) | 12 (12.9) | 7 (12.5) | 0.94 |
Intra-abdominal infection | 62 (41.6) | 45 (48.3) | 17 (30.3) | 0.031 |
Neutropenia | 34 (22.8) | 16 (17.2) | 18 (32.1) | 0.035 |
Cancer CT | 38 (25.5) | 18 (19.3) | 20 (35.7) | 0.026 |
CA-BSI | 27 (18.1) | 22 (23.6) | 5 (8.9) | 0.024 |
CVC | 123 (82.5) | 80 (86) | 43 (76.7) | 0.15 |
Early CVC removal | 73 /123 (59.3) | 55/80 (68.7) | 18 /43 (41.8) | 0.004 |
Total parenteral nutrition | 49 (32.8) | 36 (38.7) | 13 (23.2) | 0.034 |
Empiric antifungal therapy | 35 (23.8) | 27 (29.6) | 8 (14.3) | 0.033 |
Steroid use | 40 (26.8) | 20 (21.5) | 20 (35.7) | 0.08 |
Time to antifungal therapy median (IQR) | 2 (1–3) | 2 (1–2) | 2 (1–3) | 0.165 |
Initial treatment | ||||
Echinocandin | 64 (42.9) | 42 (45.1) | 22 (39.1) | 0.48 |
Caspofungin | 43 (28.8) | 27 (29) | 16 (28.5) | 0.89 |
Anidulafungin | 21 (14.1) | 15 (16.1) | 6 (11.3) | 0.4 |
AmB-d | 61 (40.9) | 35 (37.6) | 26 (46.4) | 0.29 |
Azoles | 25 (16.7) | 16 (17.2) | 9 (16) | 0.85 |
Fluconazole | 24 (16.1) | 15 (16.1) | 9 (16) | 0.95 |
Voriconazole | 1 (0.6) | 1 (1) | – | – |
Definitive treatment | ||||
Echinocandin | 56 (37.5) | 36 (38.7) | 20 (35.7) | 0.71 |
Caspofungin | 31 (20.8) | 17 (18.2) | 14 (25) | 0.34 |
Anidulafungin | 25 (16.7) | 19 (20.4) | 6 (10.7) | 0.23 |
AmB-d | 46 (30.8) | 21 (22.5) | 25 (44.6) | 0.005 |
Azoles | 47 (31.5) | 36 (38.7) | 11 (19.6) | 0.015 |
Fluconazole | 41 (27.5) | 31 (33.3) | 10 (17.8) | 0.4 |
Voriconazole | 6 (4) | 5 (5.3) | 1 (1.8) | 0.27 |
Inappropriate initial antifungal treatment | 13 (8.7) | 9 (9.6) | 4 (7.1) | 0.59 |
Inappropriate definitive antifungal treatment | 8 (5.3) | 6 (6.4) | 2 (3.5) | 0.36 |
Inappropriate initial and/or definitive treatment | 16 (10.7) | 11 (11.8) | 5 (8.9) | 0.58 |
Non-albicans CBSI | 89 (59.7) | 62 (66.6) | 27 (48.2) | 0.026 |
C. tropicalis | 35 (24) | 19 (20) | 16 (29) | 0.25 |
C. glabrata | 28 (19) | 19 (20.4) | 9 (16) | 0.5 |
C. parapsilosis | 16 (10.7) | 15 (16) | 1 (1.8) | 0.006 |
IQR interquartile range, APACHE acute physiology and chronic health evaluation, CT chemotherapy, CA-BSI catheter associated blood stream infection, CVC central venous catheter, AmB-d amphotericin B-deoxycholate, CBSI candida blood stream infection